不同剂量吉西他滨联合卡铂一线治疗晚期非小细胞肺癌的临床疗效  

Clinical Analysis of Gemcitabine with Two Dose Levels Plus Carboplatin in the First-line Treatment for Advanced Nonsmall Cell Lung Cancer

作　　者：张贝贝[1] 宋正波[1] 何春晓[1] 余新民[1] 娄广媛[1] 洪丹[1] 古翠萍[1] 张沂平[1] 

机构地区：[1]浙江省肿瘤医院,浙江省胸部肿瘤(肺,食管)诊治技术研究重点实验室,浙江杭州310022

出　　处：《肿瘤学杂志》2013年第12期977-980,共4页Journal of Chinese Oncology

基　　金：卫生科技发展研究中心课题基金(W2012FZ134);浙江省自然基金(LY13H160024);吴阶平医学基金(320.6750.11091;320.6750.11059)

摘　　要：[目的]比较不同剂量吉西他滨联合卡铂一线治疗晚期非小细胞肺癌的疗效和不良反应。[方法]回顾性分析行一线GC方案化疗的晚期非小细胞肺癌患者,共83例,均接受吉西他滨1250mg/m2(38例)或1000mg/m2(45例)联合卡铂(AUC=5)化疗。Kaplan-Meier法进行生存分析和比较。[结果]吉西他滨高剂量组(1250mg/m2)中位无进展生存期为5.2个月,低剂量组(1000mg/m2)中位无进展生存期为4.8个月(P=0.67),中位总生存期分别为14.5个月和15.8个月,差异亦无统计学意义(P=0.65)。两组有效率分别为31.6%和35.6%(P=0.70),疾病控制率分别为78.9%和73.3%(P=0.55)。吉西他滨高剂量组血小板降低比例高于低剂量组。[结论]与1250mg/m2化疗组相比,吉西他滨1000mg/m2联合卡铂一线治疗晚期非小细胞肺癌患者疗效及生存期相当,但不良反应降低。[Purpose] To investigate the efficacy and toxicity of gemcitabine with different dose plus carboplatin in the first-line treatment for advanced NSCLC.[Methods] Eighty-three NSCLC patients treated with gemcitabine（1250mg/m2or 1000mg/m2） and carboplatin（AUC=5） were retrospectively reviewed.Survival analysis was evaluated by Kaplan-Meier method.[Results] The progression-free survival（PFS） in high-dose group（1250mg/m2） and low-dose group（1000mg/m2）was 5.2 months and 4.8months and median overall survival（OS） was 14.5 months and 15.8 months respectively,also without significant difference in both groups（P0.05）.The response rates in highdose group and low-dose group were 31.6% and 35.6%（P=0.70）,and the disease control rate were 78.9% and 73.3% respectively（P=0.55）.The incidence of thrombocytopenia was higher in high-dose group than that in low-dose group.[Conclusion] Gemcitabine（1000mg/m2） plus carboplatin regimen has a similar efficacy and lower toxicity with gemcitabine（1250mg/m2） plus carboplatin regimen in the first-line treatment for advanced NSCLC.

关 键 词：肺肿瘤 化疗 吉西他滨 

分 类 号：R734.2[医药卫生—肿瘤]